Form 8-K - Current report:
SEC Accession No. 0000950170-23-009175
Filing Date
2023-03-22
Accepted
2023-03-22 16:10:36
Documents
13
Period of Report
2023-03-22
Items
Item 2.02: Results of Operations and Financial Condition
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K asmb-20230322.htm   iXBRL 8-K 65167
2 EX-99.1 asmb-ex99_1.htm EX-99 279056
  Complete submission text file 0000950170-23-009175.txt   482080

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT asmb-20230322_pre.xml EX-101.PRE 10679
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT asmb-20230322.xsd EX-101.SCH 2483
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT asmb-20230322_lab.xml EX-101.LAB 17018
7 EXTRACTED XBRL INSTANCE DOCUMENT asmb-20230322_htm.xml XML 4547
Mailing Address 331 OYSTER POINT BLVD. FOURTH FLOOR SOUTH SAN FRANCISCO CA 94080
Business Address 331 OYSTER POINT BLVD. FOURTH FLOOR SOUTH SAN FRANCISCO CA 94080 (833) 409-4583
ASSEMBLY BIOSCIENCES, INC. (Filer) CIK: 0001426800 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35005 | Film No.: 23753031
SIC: 2834 Pharmaceutical Preparations